By
Trending Posts
Is Portal Biotech’s $35M Series A Set to…
Key Takeaways Transforming Protein Sequencing With AI and Nanopore InnovationPortal Biotech, a London-based pioneer in proteomics, is aiming…
Is the NHS’s New AI Warning System About…
Key Takeaways AI-Powered Safety OverhaulThe NHS announced it will become the first healthcare system worldwide to deploy an…
How Is LogicFlo AI’s $2.7M Seed Round Fueling…
Key Takeaways Transforming Compliance-Driven Workflows With AI AgentsLogicFlo AI, founded by Udith Vaidyanathan and Arun Ramakrishnan, is reinventing…
How Is XtalPi’s Expanded Collaboration With Pfizer Set…
Key Takeaways Empowering Next-Gen AI Platforms for Predictive Drug DiscoveryXtalPi and Pfizer have extended their strategic partnership to…
Is AI-Engineered HMBD-002 the Next Big Immunotherapy? Hummingbird…
Key Highlights Strategic Global Licensing Deal Hummingbird Bioscience has signed a worldwide licensing agreement with Percheron Therapeutics for…
Can ProFound Therapeutics and Novartis’ $750M AI-Driven Cardiovascular…
Key Highlights AI Meets Proteomics: A New Paradigm in Cardiovascular DiscoveryIn a bold step toward AI-enabled medicine, ProFound…
Is Insilico’s AI-Driven UAE University Alliance the Catalyst…
Key Highlights Academic Meets AI Innovation in UAEInsilico Medicine, a leader in generative AI for drug discovery, has…
How Abridge’s $5.3B AI Surge Is Transforming Clinical…
Key Insights: Andreessen Horowitz Leads $300M Bet on Abridge’s Healthcare AI VisionAndreessen Horowitz (A16z) has doubled down on…
Why Sutter Health’s Strategic AI Partnership with Aidoc…
Key Highlights Strategic Collaboration to Scale Clinical AISutter Health has announced a multi-year strategic partnership with Aidoc, embedding…
Trending Posts
Latest Stories
Can Absci’s AI-Powered Drug Platform Disrupt $600M+ Biopharma Pipelines by 2026?
Absci blends AI and biology—end-to-endUnlike other AI drug startups that rely on outsourcing, Absci integrates…
Can Chugai (Roche subsidiary) and Gero’s $250M AI-Driven Alliance Unlock a New Era in Anti-Aging Therapies?
Key Takeaways: AI-Powered Target Discovery Meets World-Class Antibody EngineeringThe joint research and license agreement between…
Could AbbVie and IGI’s $1.9B Bet on AI-Engineered Trispecific Antibody Signal a New Era for Relapsed Myeloma Treatment?
Key Highlights: AbbVie Accelerates into AI-Powered Immuno-OncologyAbbVie has entered a global licensing agreement worth up…
Can Personalis and Tempus Leverage AI to Transform Cancer Recurrence Detection for 150,000 Colorectal Patients? Strategic Expansion Deepens MRD Leadership
Key Highlights AI at the Core of Next-Gen Recurrence MonitoringThe expansion of Personalis’ NeXT Personal®…
Gallery
